Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533590 | 0.85 | PIM1 (0.44) | BACE1METAP2PIM1PIM2EPHX2 | |
| SCHEMBL533992 | 0.81 | TSHR (0.38) | TSHR | |
| SCHEMBL533400 | 0.81 | ALDH1A1 (0.36) | KDM4ETSHRKIF11 | |
| SCHEMBL207069 | 0.74 | CYP1A2 (0.38) | BACE1PGRKDM4E | |
| SCHEMBL534223 | 0.73 | PIM1 (0.41) | PIM1EPHX2KDM4ESCN4AMAPK1 | |
| SCHEMBL694198 | 0.72 | PGR (0.56) | EPHX2PGRKIF11 | |
| SCHEMBL5543588 | 0.70 | PIM1 (0.32) | PIM1PIM2 | |
| SCHEMBL17870639 | 0.69 | CA12 (0.44) | KDM4E | |
| SCHEMBL4148062 | 0.69 | ALDH1A1 (0.41) | KDM4E | |
| SCHEMBL207471 | 0.69 | CYP2A6 (0.38) | BACE1METAP2PIM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1204126-C | Process for preparing pyridazin-2-one derivs. | SUMITOMO CHEMICAL CO (JP) | 2005-06-01 | — | — | CN | disclosed |
| EP-1137641-B1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-6500951-B1 | RING CLOSING A CARBOXYLIC ACID DERIVATIVE IN PRESENCE OF A NITROGEN CONTAINING AROMATIC COMPOUND AND A BORON COMPOUND; HIGH YIELD AND PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| CN-1334805-A | Process for preparing pyridazin-2-one derivs. | SUMITOMO CHEMICAL CO (JP) | 2002-02-06 | — | — | CN | disclosed |
| EP-1137641-A1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034249-A1 | PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | BACE1 3399/4885METAP2 4595/4885PIM1 3129/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | BACE1 4333/4885METAP2 458/4885PIM1 4327/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | BACE1 4459/4885METAP2 477/4885PIM1 4427/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | BACE1 3072/4885METAP2 1892/4885PIM1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.